MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.51
+0.53
+10.64%
After Hours: 5.45 -0.06 -1.09% 16:31 05/14 EDT
OPEN
5.03
PREV CLOSE
4.980
HIGH
5.54
LOW
4.990
VOLUME
2.48M
TURNOVER
--
52 WEEK HIGH
5.19
52 WEEK LOW
2.875
MARKET CAP
569.54M
P/E (TTM)
8.11
1D
5D
1M
3M
1Y
5Y
Catalyst Pharmaceuticals Inc. stock outperforms market on strong trading day
Shares of Catalyst Pharmaceuticals Inc. advanced 2.53% to $4.86 Wednesday, on what proved to be an all-around poor trading session for the stock market, with...
marketwatch.com · 1d ago
--Cantor Fitzgerald Adjusts Price Target on Catalyst Pharmaceuticals to $11 From $8, Maintains Overweight Rating
MT Newswires · 2d ago
Catalyst Pharmaceuticals Inc. stock falls Tuesday, underperforms market
Shares of Catalyst Pharmaceuticals Inc. shed 1.66% to $4.74 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the...
marketwatch.com · 2d ago
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
Zacks.com · 3d ago
Catalyst Pharmaceuticals, Inc. to Host Earnings Call
ACCESSWIRE · 3d ago
8-K: CATALYST PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- NASDAQ false 0001369568 0001369568 2021-05-10 2021-05-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 3d ago
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Is Going Strong: Is the Market Following Fundamentals?
Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 11...
Simply Wall St. · 3d ago
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings Estimates
Zacks.com · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPRX. Analyze the recent business situations of Catalyst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CPRX stock price target is 7.50 with a high estimate of 9.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 198
Institutional Holdings: 89.08M
% Owned: 86.18%
Shares Outstanding: 103.36M
TypeInstitutionsShares
Increased
41
4.90M
New
18
4.77M
Decreased
50
6.29M
Sold Out
23
4.35M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.15%
Key Executives
Chairman/Chief Executive Officer/President/Director
Patrick McEnany
Chief Financial Officer/Vice President/Treasurer
Alicia Grande
Chief Operating Officer/Chief Scientific Officer
Steven Miller
Executive Vice President
David Muth
Chief Compliance Officer
Brian Elsbernd
Other
Jeffrey Del Carmen
Other
Gary Ingenito
Vice President - Business Development
David Ailinger
Lead Director/Independent Director
Charles O'Keeffe
Independent Director
Richard Daly
Independent Director
Donald Denkhaus
Independent Director
David Tierney
No Data
  • All
  • Financials
  • Insiders
More
About CPRX
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.